Income Statement
ZENAS BIOPHARMA, INC.
ZBIO
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
10.00 | 5.00 |
|
Cost of Revenue
|
- | - |
|
Gross Profit
|
10.00 | 5.00 |
|
Operating Expenses
|
393.06 | 168.89 |
|
Research & Development
|
168.06 | 139.14 |
|
Selling, General & Administrative
|
53.32 | 29.75 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-383.06 | -163.89 |
|
Non-Operating Income
|
5.24 | 7.33 |
|
Interest Income
|
12.15 | - |
|
Interest Expense
|
- | - |
|
Other Non-Op Income / Expense
|
0.42 | 8.18 |
|
Income Before Tax
|
-377.82 | -156.56 |
|
Income Tax Expense
|
-0.08 | 0.43 |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-377.74 | -156.99 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-383.06 | -163.89 |
|
Earnings Per Share (Basic)
|
-8.44 | -11.89 |
|
Diluted EPS
|
-8.44 | -11.89 |
|
Weighted Average Shares
|
44.73 | 13.20 |
|
Diluted Weighted Avg Shares
|
44.73 | 13.20 |
|
Comprehensive Income
|
-378.00 | -156.83 |